Melatonin: Nursing Drug Guide, Sedation Stacking & NCLEX Review

Melatonin is available as prescription prolonged-release tablets, immediate-release products, liquids, and widely sold dietary supplements. Nursing practice must match the ordered formulation to administration technique—prolonged-release behavior is lost when tablets are crushed.

• Prescription prolonged-release: Circadin 2 mg (UK/EU/Australia and other markets per local formulary)
• OTC / supplement forms: Immediate-release tablets, gummies, liquids—content and quality may vary; not interchangeable milligram-for-milligram with Circadin without prescriber direction
• Related sedating agents: doxepin, diphenhydramine, and lorazepam—different mechanisms; duplicate bedtime sedatives increase fall and sedation risk

Per Circadin Summary of Product Characteristics (SmPC) and EMA product information:

• Licensed indication (Circadin): Short-term treatment of primary insomnia characterised by poor quality of sleep in adults aged 55 and over
• Duration: Up to 13 weeks per SmPC for this licensed use

Nurses also encounter melatonin for insomnia and circadian disruption in other age groups or conditions when prescribed off-label or via national pathways (e.g. paediatric sleep disorders per specialist protocols). Follow prescriber orders and local product labeling—do not assume supplement dosing equals prescription prolonged-release dosing.

Melatonin is a pineal hormone involved in circadian rhythm and sleep-wake timing. Exogenous melatonin acts at MT1 and MT2 receptors, promoting sleep onset and alignment with the dark phase. Circadin releases melatonin over hours to mimic the natural night-time profile; crushing the tablet shifts toward immediate release.

Melatonin is not a general sedative-hypnotic like benzodiazepines—it supports timing of sleep. Expectations should focus on sleep quality and latency rather than instant unconsciousness.

Oral route. Dosing depends on product (prolonged-release versus immediate-release) and jurisdiction.

Circadin prolonged-release 2 mg (SmPC / EMA)

↔On a small screen, swipe or scroll sideways to see the full table.

Paediatric and higher-dose prescribing (NHS guidance — when locally used)

UK NHS patient information describes specialist use in children with condition-related sleep problems, with gradual titration up to 10 mg once daily in some cases. That pathway is not the Circadin licensed adult indication—verify specialist orders and local policy. Not specified in the reviewed Circadin SmPC for routine paediatric use.

• Absorption: Complete in adults; may be ~50% lower in older adults; bioavailability ~15% with substantial first-pass metabolism per SmPC
• Food effect: Take after food—fed state delays and lowers peak concentration versus fasted administration
• T_max: About 3 hours in fed state with Circadin
• Metabolism: Hepatic via CYP1A1, CYP1A2, and possibly CYP2C19
• Half-life: Approximately 3.5–4 hours; metabolites excreted renally within ~12 hours
• Elderly: Higher exposure (AUC/C_max) than younger adults—reinforces sedation monitoring

Answer these before the first dose or when reconciling home sleep products:

• Correct patient, drug, strength, formulation (prolonged-release versus immediate-release), route, and scheduled time
• Tablet integrity: Prolonged-release product intact—not crushed, chewed, or split unless prescriber/pharmacy explicitly directs (SmPC: swallow whole)
• Timing: Ordered for 1–2 hours before bedtime after food (Circadin)
• Duplicate sedatives: MAR plus home gummies, hypnotics, antihistamines, or opioid sedatives
• Alcohol intake planned with dose—labeling says avoid alcohol before, during, and after Circadin
• Fluvoxamine or other strong CYP1A2 inhibitors—combination with fluvoxamine should be avoided per SmPC
• Hepatic impairment—Circadin not recommended; published data show elevated daytime melatonin with decreased clearance
• Autoimmune disease—not recommended per SmPC (insufficient clinical data)
• Renal impairment—pharmacokinetics not studied; use caution per SmPC
• Pregnancy or breastfeeding—not recommended per SmPC; discuss with prescriber
• Driving / hazardous work next morning—drowsiness may persist; assess alertness

• Hypersensitivity to melatonin or any excipient (Circadin SmPC)
• Galactose intolerance / Lapp lactase deficiency / glucose-galactose malabsorption—Circadin contains lactose

Not recommended (warnings, not absolute contraindications in SmPC): hepatic impairment, autoimmune disease (e.g. lupus, rheumatoid arthritis)—hold and clarify with prescriber when these appear on the chart.

↔On a small screen, swipe or scroll sideways to see the full table.

• Prolonged-release (Circadin): Swallow tablet whole with water after food, 1–2 hours before bedtime
• Do not crush, chew, or divide unless pharmacy prepares an alternative with prescriber approval—crushing alters release and sedation profile
• Document formulation (Circadin 2 mg PR versus supplement mg strength)
• Evening dose only—daytime dosing can worsen sedation and circadian disruption

• Reduced sleep latency and improved subjective sleep quality over days to weeks (clinical trials per SmPC)
• Morning alertness preserved in trials at 2 mg—still assess each patient for grogginess
• No rebound insomnia reported in withdrawal periods in SmPC trial summaries—still taper per prescriber when stopping long-term use
• If no benefit after an appropriate trial, prescriber may adjust therapy—not nurse-led dose doubling with supplements

• Excessive sedation, unresponsiveness, or inability to arouse—especially with hypnotics, alcohol, or crushed prolonged-release dose
• Fall with head injury or new confusion after bedtime sedative stack
• Angioedema or hypersensitivity—postmarketing reports per SmPC; stop drug and escalate
• New severe mood change, agitation, or suicidal ideation—psychiatric adverse effects listed in labeling; involve mental health team urgently per protocol
• Severe headache, chest pain, or palpitations—evaluate per prescriber
• Worsening sleep despite correct administration—may signal wrong formulation or interaction

Common and clinically important effects from Circadin clinical trials and labeling (frequencies per SmPC MedDRA categories):

↔On a small screen, swipe or scroll sideways to see the full table.

Rare/postmarketing: angioedema, syncope, seizures, altered libido, and others per SmPC. Report suspected adverse reactions per local pharmacovigilance requirements.

Per Circadin SmPC: postmarketing overdoses most often caused somnolence (usually mild to moderate). Literature reports describe daily doses up to 300 mg without clinically significant reactions in some cases. NHS patient information notes 1–2 extra 2 mg tablets are unlikely to cause serious harm in many patients—still assess and escalate per clinical picture.

Antidote

No specific antidote is described in the reviewed prescribing information. Expect drowsiness; active substance clearance within about 12 hours. Treatment is supportive—no special treatment required for many cases per SmPC.

• Melatonin vs meloxicam—verify generic name on MAR; different drug class and indication
• Circadin 2 mg PR vs immediate-release melatonin / gummies—do not substitute without prescriber and pharmacy approval
• Home “sleep aid” bottles—may contain melatonin plus herbal sedatives; reconcile all products
• Combination homeopathic or multi-ingredient melatonin products on some markets—not equivalent to single-ingredient prescription melatonin
• Sound-alike orders: “melatonin” confused with “Mellaril” (thioridazine) or other night meds—read back generic name and strength

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• Sedation level and excessive sleepiness—especially first doses and when sedatives are co-prescribed
• Sleep quality, latency, and morning alertness (patient report and nursing observation)
• Blood pressure if hypertension symptoms or listed adverse effects occur
• Mood, anxiety, nightmares, or behavioral changes
• Fall risk on night rounds and ambulation the morning after dose
• Liver history and any new abnormal liver function tests if reported

Routine melatonin therapy does not require specific scheduled labs in the reviewed prescribing information.

Document

• Product name, strength, formulation (PR versus IR), time, and route
• Whether tablet was given whole after food in the correct pre-bedtime window
• Home supplement reconciliation and alcohol/hypnotic screening
• Interaction checks (e.g. fluvoxamine) and prescriber notifications
• Patient response: sleep improvement versus next-day grogginess

• Take after food, 1–2 hours before bedtime, and swallow prolonged-release tablets whole
• Do not drink alcohol with melatonin—reduces benefit and increases impairment per labeling
• Do not combine with other bedtime sedatives unless the prescriber directs—includes OTC sleep gummies and antihistamines
• Avoid driving or hazardous tasks if groggy the next morning
• Bring all sleep products to appointments; supplements may differ from prescription melatonin
• Short-term use for licensed adult indication is up to 13 weeks—longer courses only per prescriber
• Pregnancy, breastfeeding, liver disease, or autoimmune conditions—discuss with prescriber before starting
• Seek urgent care for facial swelling, trouble breathing, or severe mood changes

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for melatonin using a tabbed case (MAR, labs, history, nursing notes), then priority action, cue recognition, trend interpretation, matrix urgency sorting, clinical judgment, and documentation cloze—recognise cues → analyse → prioritise → act → evaluate outcomes (prolonged-release integrity, sedative stacking, and fluvoxamine interaction safety).

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.